Zacks Small Cap Has Pessimistic View of ENSC FY2025 Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Investment analysts at Zacks Small Cap lowered their FY2025 earnings per share (EPS) estimates for shares of Ensysce Biosciences in a note issued to investors on Monday, November 17th. Zacks Small Cap analyst B. Sorensen now expects that the company will earn ($4.73) per share for the year, down from their prior estimate of ($3.68). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share. Zacks Small Cap also issued estimates for Ensysce Biosciences’ Q4 2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.29) EPS.

Other analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Ensysce Biosciences to a “hold” rating in a report on Saturday, October 25th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Ensysce Biosciences Stock Down 1.5%

NASDAQ:ENSC opened at $1.93 on Wednesday. The company’s 50 day moving average is $2.21 and its 200-day moving average is $2.19. Ensysce Biosciences has a 12 month low of $1.62 and a 12 month high of $11.13. The firm has a market cap of $6.83 million, a price-to-earnings ratio of -0.30 and a beta of 1.14.

Ensysce Biosciences (NASDAQ:ENSC) last posted its earnings results on Friday, November 14th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.44). The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.70 million. Ensysce Biosciences had a negative return on equity of 437.31% and a negative net margin of 244.47%.

Institutional Investors Weigh In On Ensysce Biosciences

Several large investors have recently modified their holdings of ENSC. TRU Independence Asset Management 2 LLC bought a new stake in Ensysce Biosciences in the third quarter valued at $25,000. Citadel Advisors LLC bought a new position in shares of Ensysce Biosciences during the third quarter valued at $34,000. Virtu Financial LLC acquired a new stake in shares of Ensysce Biosciences in the 3rd quarter valued at $34,000. Adage Capital Partners GP L.L.C. grew its holdings in shares of Ensysce Biosciences by 49.4% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 74,711 shares of the company’s stock worth $191,000 after purchasing an additional 24,711 shares during the last quarter. Finally, Murchinson Ltd. acquired a new stake in shares of Ensysce Biosciences during the 1st quarter worth about $358,000. 5.63% of the stock is currently owned by institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.